This study explores the variation of PIV across BC subtypes, with a focus on triple-negative BC (TNBC), hormone receptor positive and negative (HR+ and HR-) cancers, and racial disparities in immune response.<h4>Methods</h4>A retrospective review of laboratory and clinical data of 2,597 BC patients treated between 2012-2022 was conducted. Here, NR4A1 is linked to breast cancer.